Type 2 & other diabetes

Prognostic value of computed tomography-derived fractional flow reserve in patients with diabetes mellitus and unstable angina

Cardiovasc DiabetolPublished Retrospective cohort study

Authors' conclusion

CT-FFR demonstrated significant diagnostic performance using invasive FFR as the reference standard and proved to be an important predictive tool for assessing prognosis not only in calcified lesions but also in lesions with a CACS score of zero in patients with T2DM and UA. CT-FFR may serve as a valuable tool for guiding treatment decisions in these patients.

Study context

Population
Patients with T2D and unstable angina who underwent coronary computed tomography angiography (CTA) with at least one visible calcification site; subset completed invasive coronary angiography and invasive fractional flow reserve (FFR)1,091 with invasive FFR
Participants
3,392 patients
Exposure
CT-FFR ≤ 0.80 vs CT-FFR > 0.80
Outcome
Diagnostic performance of CT-FFR vs invasive FFR (per patient)

Main finding

As reported in the abstract

GroupAccuracySensitivitySpecificityPPVNPVAUC
CT-FFR84.8%84.6%85.1%84.7%85.0%84.8%

CT-FFR

Accuracy84.8%
Sensitivity84.6%
Specificity85.1%
PPV84.7%
NPV85.0%
AUC84.8%

Observational data: associations, not effects.

Further findings

Lesion and calcification characteristics

Degree of stenosis, lesion length, rate of bifurcation lesions, diffuse lesions, occlusion, calcium volume and coronary artery calcification score (CACS) significantly higher with CT-FFR ≤ 0.8 vs CT-FFR > 0.8
Minimum cross-sectional area smaller with CT-FFR ≤ 0.8 vs CT-FFR > 0.8

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Prognostic value of computed tomography-derived fractional flow reserve in patients with diabetes mellitus and unstable angina. Cardiovasc Diabetol. Published 8 November 2024. doi:10.1186/s12933-024-02493-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.